Back to top

AstraZeneca’s BIFANG Study Targets China CRSwNP Market With Tezspire

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The BIFANG study, officially titled “A Multicentre, Single-Arm, Phas...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)